| Accession | Title | Series type(s) | Organism(s) | Samples | GDS | Supplementary | Contact | Release date |
|---|---|---|---|---|---|---|---|---|
 Filter
|
Expression profiling by array
|
Robert W Hoffman
|
||||||
| GSE88887 |
Gene expression and pharmacodynamic-induced changes in 1760 SLE Patients from two phase III trials of B cell activating factor blockade with tabalumab
|
|
3146 | Robert W Hoffman | Oct 25, 2016 | |||
| GSE88884 |
Gene expression changes in baseline SLE patients vs. healthy controls from two phase III trials (ILLUMINATE-1 and ILLUMINATE-2) of B cell activating factor blockade with tabalumab
|
|
1820 | Robert W Hoffman | Oct 25, 2016 | |||
| GSE88885 |
Pharmacodynamic-induced changes in SLE Patients from the ILLUMINATE-1 phase III trial of B cell activating factor blockade with tabalumab
|
|
908 | Robert W Hoffman | Oct 25, 2016 | |||
| GSE88886 |
Pharmacodynamic-induced changes in SLE Patients from the ILLUMINATE-2 phase III trial of B cell activating factor blockade with tabalumab
|
|
418 | Robert W Hoffman | Oct 25, 2016 | |||
| GSE61635 |
Gene expression in RNP autoantibody+ systemic lupus erythematosus (SLE) patient blood
|
|
129 | Robert W Hoffman | Jan 01, 2015 |
